People · Operator
Named in public records as an officer, director or promoter · active 2012–2024 · SaaS / Software, Other Health Care, Pharma, Other Technology, Healthtech, Other
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Cortex, Inc. | — | SaaS / Software | Series D+ | $133.4M | $1.9B | 2023 |
| Spirox, Inc. | — | Other Health Care | Series C | $98.2M | $1.0B | 2013 |
| Advanced Cardiac Therapeutics Inc | — | Pharma | Series C | $64.1M | $1.6B | 2014 |
| CV Ingenuity Corp. | — | Other Technology | Series B | $56.3M | $339.2M | 2012 |
| XII Medical, Inc. | — | Healthtech | Series B | $45.1M | $146.0M | 2020 |
| Genetic Foresight, Inc. | — | Other | Series B | $17.6M | $284.7M | 2020 |
| Protaryx Medical Inc. | — | Healthtech | Series A | $8.1M | $183.1M | 2020 |
| Mimosa Medical, Inc. | — | Other | Seed | $2.2M | $8.3M | 2014 |
| Verix Health, Inc. | — | Biotechnology | Seed | $1.5M | $66.6M | 2019 |
| Atriomx, Inc. | — | Other | Pre-Seed | $1.0M | $18.0M | 2021 |
Duke Rohlen at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Duke Rohlen on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Doug Koo | 6 | 8 |
| Aftab Kherani | 5 | 9 |
| Ryan Drant | 2 | 24 |
| Justin Klein | 2 | 6 |
| Tony Natale | 2 | 5 |
| Anthony J. Natale | 2 | 5 |
| Shane Kreidel | 2 | 2 |
| Robert Thomas | 1 | 8 |
| Douglas Koo | 1 | 7 |
| Roy Tanaka | 1 | 6 |
| Richard B. Emmitt | 1 | 6 |
| Avi Naider | 1 | 6 |
| Camille Samuels | 1 | 6 |
| Michael Henson | 1 | 5 |
| STACY ENXING SENG | 1 | 5 |
| Benjamin Pless | 1 | 5 |
| Samuel Lee | 1 | 4 |
| Anthony Natale | 1 | 4 |
| William Olson | 1 | 3 |
| Louis Cannon | 1 | 3 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.